VI

Vimian Group AB (VIMIAN)

HealthcareDiagnostics & Research
31.00SEK
-0.48%
Magic Rank
#134
Earnings Yield
0.3%
Return on Capital
43.5%
Market Cap
15.9B

Performance vs S&P 500 (5Y)

VIMIAN.ST
S&P 500

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name. It also provides procurement and tech-driven operations, such as online marketing, and education and HR, as well as a community for veterinary clinics through a membership-based platform under the VetFamily brand name; and orthopedic implants for veterinarians and universities under the Movora brand name. Vimian Group AB (publ) was incorporated in 2020 and is headquartered in Stockholm, Sweden.

Magic Formula Analysis

Enterprise Value16.1B
Market / Universe
se
Sweden

"A company with high ROC and high EY is statistically more likely to outperform the market."

Key Indicators

P/E Ratio39.27
Dividend YieldN/A
Debt to Equity0.22
Gross Margin16.8%